2-氨基-3,5-二甲基苯甲醛 | 70128-12-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-3,5-二甲基苯甲醛
• 英文名称: 2-amino-3,5-dimethyl-benzaldehyde
• 英文别名: 2-Amino-mesitylenaldehyd；2-Amino-3,5-dimethylbenzaldehyde
• CAS: 70128-12-0
• 化学式: C₉H₁₁NO
• mdl: MFCD18824349
• 分子量: 149.192
• InChiKey: PSDMVINPHZQMGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-氨基-3,5-二甲基苯甲醛 在 吡啶 作用下， 以 四氢呋喃 为溶剂， 反应 7.0h， 生成 1-(3,5-dimethyl-2-(tosylamino)phenyl)prop-2-yn-1-ol
  参考文献：
  名称：

  通过N-碘代琥珀酰亚胺介导的1-（2'-苯胺基）prop-2-yn-1-ols在水中的环化反应，无金属合成1 H-吲哚-2-甲醛。（R）-calindol的形式合成

  摘要：

  描述了一种由N-碘琥珀酰亚胺（NIS）介导的方法，该方法可通过1-（2-氨基苯基）丙-2-yn-1-醇的环异构化有效地制备1 H-吲哚-2-甲醛。该反应操作简便易行，并且可通过低成本，易于获得且生态友好的多种醇底物以良好至极佳的收率（48-91％）完成。该方法作为吲哚合成的潜在放大策略的实用性通过一个实例的大规模合成以优异的产率得到了例证。（R）-卡林多醇的正式合成中也证明了该化学方法的合成效用。

  DOI：

  10.1016/j.tet.2013.06.032
• 作为产物：
  描述：

  3,5-二甲基-2-硝基苯甲醛 在 氨 、 iron(II) sulfate 作用下， 生成 2-氨基-3,5-二甲基苯甲醛
  参考文献：
  名称：

  Interpretation, Design, and Analysis of Gene Array Expression Experiments

  摘要：

  Experiments using arrays of cDNA targets to compare patterns of gene expression are beginning to play a prominent role in biogerontology, but drawing reliable conclusions from the resulting data sets requires careful application of statistical methods that discriminate chance events from those likely to reflect real differences among the samples under study. This essay discusses flaws in the logic of studies that base their conclusions on ratio calculations alone, reviews the multiple comparison traps inherent in high throughput systems that test a very large number of mRNAs simultaneously, and advocates a two-stage design in which significance testing applied to exploratory data is used to guide a second round of hypothesis-testing experiments conducted in a separate set of experimental samples.

  DOI：

  10.1093/gerona/56.2.b52

文献信息

• Chiral Phosphoric-Acid-Catalyzed Cascade Prins Cyclization
  作者：Huai-Ri Sun、Qingyang Zhao、Hui Yang、Sen Yang、Bo-Bo Gou、Jie Chen、Ling Zhou

  DOI：10.1021/acs.orglett.9b02714

  日期：2019.9.6

  Asymmetric Prins cyclization of in situ generated quinone methides and o-aminobenzaldehyde has been developed with chiral phosphoric acid as an efficient catalyst. This unconventional method provides a facile access to diverse functionalized trans-fused pyrano-/furo-tetrahydroquinoline derivatives in excellent yield and with excellent diastereo- and enantioselectivities (up to 99% yield and 99% ee)

  已经开发了以手性磷酸为有效催化剂的原位生成的醌甲基化物和邻氨基苯甲醛的不对称Prins环化反应。这种非常规的方法可以轻松获得各种功能化的反式吡喃//呋喃-四氢喹啉衍生物，且产率高，非对映和对映选择性（产率高达99％，ee高达99％）。力学研究表明，三个相邻的三级立体中心是通过C–O，CC和C–N键的顺序形成而构建的。
• Gold(I)-Catalyzed Unprecedented Rearrangement Reaction Between 2-Aminobenzaldehydes with Propargyl Amines: An Expedient Route to 3-Aminoquinolines
  作者：Nitin T. Patil、Vivek S. Raut、Valmik S. Shinde、Gaddamanugu Gayatri、G. Narahari Sastry

  DOI：10.1002/chem.201103668

  日期：2012.4.27

  aminoquinolines: A gold(I)‐catalyzed unprecedented rearrangement reaction between 2‐aminobenzaldehydes with propargyl amine was studied. The study provided, for the first time, direct access to 3‐aminoquinolines in one step starting from readily available starting materials (see scheme). Elegantly designed experiments were employed to unravel the mechanism of this unprecedented rearrangement, which are corroborated

  接触氨基喹啉：研究了2-氨基苯甲醛与炔丙基胺之间的金（I）催化的前所未有的重排反应。该研究首次从容易获得的起始原料开始，一步就可以直接获得3-氨基喹啉（见方案）。精心设计的实验用于阐明这种前所未有的重排的机制，这一点已通过DFT计算得到了证实。
• Cooperative Catalysis with Metal and Secondary Amine: Synthesis of 2-Substituted Quinolines via Addition/Cycloisomerization Cascade
  作者：Nitin T. Patil、Vivek S. Raut

  DOI：10.1021/jo101103a

  日期：2010.10.15

  A cooperative catalytic system, consisting of CuI and pyrrolidine, has been developed for an efficient synthesis of 2-substituted quinolines. A combination of both the catalysts is necessary; the use of either catalyst alone does not give the product.

  为了有效合成2-取代的喹啉，已经开发了由CuI和吡咯烷组成的协同催化体系。两种催化剂必须结合使用。单独使用任何一种催化剂都无法获得产品。
• 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF
  申请人：Kajino Masahiro

  公开号：US20090082343A1

  公开（公告）日：2009-03-26

  This invention provides a compound represented by the formula (I): wherein R 1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R 2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I), which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

  这项发明提供了一个由公式（I）表示的化合物：其中，R1是氢原子，卤素原子，羟基，硝基，可选择卤代烷基，烷氧基可选择具有取代基，酰基或氨基可选择具有取代基；R2是吡啶基，呋喃基，噻吩基，吡咯基，喹啉基，吡嗪基，嘧啶基，吡嗪啉基，吲哚基，四氢喹啉基或噻唑基，每种基团都可以有取代基；n为1或2；或其盐。此外，这项发明提供了一种安全的药物，其中包括公式（I）的化合物，该药物具有出色的凋亡抑制效果和MIF结合效果，用于预防和/或治疗心脏病，神经退行性疾病，脑血管疾病，中枢神经系统感染性疾病，创伤后疾病，脱髓鞘疾病，骨骼和关节疾病，肾脏疾病，肝脏疾病，骨髓发育不良，艾滋病，癌症等。
• Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
  申请人：Chen Xinchao

  公开号：US20120058990A1

  公开（公告）日：2012-03-08

  Abstract Compounds of a formula entitled, trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid, as a free acid or a pharmaceutically acceptable salt thereof, hydrate, and hydrate in crystalline form; pharmaceutical formulations; and methods of use are disclosed.

  本发明涉及一种名为trans-4-[[(5S)-5-[[[3,5-双三氟甲基苯基]甲基](2-甲基-2H-四唑-5-基)氨基]-2,3,4,5-四氢-7,9-二甲基-1H-1-苯并氮杂环-1-基]甲基]-环己烷羧酸的化合物，其可以是自由酸或其药学上可接受的盐，水合物以及晶体形式的水合物；药物制剂；以及使用方法。